WHO SMART Guidelines - HIV
0.3.0 - ci-build
WHO SMART Guidelines - HIV - Local Development build (v0.3.0) built by the FHIR (HL7® FHIR® Standard) Build Tools. See the Directory of published versions
Contents:
This page provides a list of the FHIR artifacts defined as part of this implementation guide.
These define activities that can be performed as part of content in this implementation guide.
| HIV.B9.DT Schedule Follow-up Test |
Schedule Follow-up Test |
These define workflows, rules, strategies, or protocols as part of content in this implementation guide.
| HIV.B2.DT Check for signs of serious illness |
Check for signs of serious illness |
| HIV.B9.DT Determine retest recommendation |
HIV restesting recommendations |
These define logic, asset collections and other libraries as part of content in this implementation guide.
| HIV.B2.DT Logic |
HIV.B2.DT Logic |
| HIV.B7.DT Logic |
Description not yet available for HIV.B7.DT Logic. |
| HIV.B9.DT Logic |
HIV.B9.DT Logic |
| HIV.IND.11 Logic |
% of opioid dependent people receiving opioid agonist maintenance treatment (OAMT) at a specified date |
| HIV.IND.12 Logic |
% of person-years of follow-up (PYFU) on OAMT among opioid dependent people |
| HIV.IND.13 Logic |
% of OAMT recipients who received treatment for at least six months |
| HIV.IND.14 Logic |
% of OAMT recipients receiving a maintenance dose greater than or equal to the recommended minimum dose |
| HIV.IND.15 Logic |
Total number of voluntary medical male circumcisions (VMMCs) performed according to national standard during the reporting period |
| HIV.IND.16 Logic |
a) Number or (b) % of adverse events during the reporting period |
| HIV.IND.18 Logic |
Number and % of people living with HIV who know their HIV status |
| HIV.IND.19 Logic |
Number of HIV tests performed (volume) and the % of HIV-positive results returned to people (positivity) |
| HIV.IND.2 Logic |
Number of people who received PrEP at least once during the reporting period |
| HIV.IND.20 Logic |
% testing positive among people who received an HIV test in the reporting period |
| HIV.IND.21 Logic |
% of people newly diagnosed with HIV initiated on ART |
| HIV.IND.22 Logic |
Number of people who were identified and tested using partner testing services and who received their results |
| HIV.IND.24 Logic |
Among those testing HIV-negative and identified as being at elevated risk for HIV acquisition, % of people who receive an HIV prevention intervention within defined period |
| HIV.IND.25 Logic |
% of people testing HIV-negative who tested again within a defined period of time after their previous test |
| HIV.IND.27 Logic |
Number and % of people on ART among all people living with HIV at the end of the reporting period |
| HIV.IND.28 Logic |
Number and % of people living with HIV on ART at the end of the last reporting period and those newly initiating ART during the current reporting period who were not on ART at the end of the current reporting period |
| HIV.IND.29 Logic |
% of people living with HIV on ART (for at least six months) who have virological suppression |
| HIV.IND.3 Logic |
% of people prescribed PrEP among those identified as being at elevated risk for HIV acquisition |
| HIV.IND.30 Logic |
Number of people living with HIV who initiated ART |
| HIV.IND.31 Logic |
% of people living with HIV who initiate ART with a CD4 count of <200 cells/mm3 |
| HIV.IND.32 Logic |
% of people living with HIV on ART (for at least six months) with viral load test results |
| HIV.IND.33 Logic |
Number and % of people living with HIV on ART who had a viral load result reviewed by six months after initiation of ART |
| HIV.IND.34 Logic |
% of people living with HIV receiving ART with VL ≥1000 copies/mL who received a follow-up viral load test within three months |
| HIV.IND.35 Logic |
% of ART patients with treatment-limiting ARV toxicity |
| HIV.IND.37 Logic |
% of HIV-positive pregnant women who are virally suppressed at labour and delivery |
| HIV.IND.38 Logic |
% of HIV-exposed infants who receive a virological test for HIV within two months (and 12 months) of birth |
| HIV.IND.39 Logic |
% of HIV-exposed infants who initiated ARV prophylaxis |
| HIV.IND.4 Logic |
Total volume of PrEP product prescribed |
| HIV.IND.40 Logic |
% of HIV-positive pregnant women who received ART during pregnancy and/or at labour and delivery |
| HIV.IND.41 Logic |
% of HIV-exposed breastfeeding infants whose mothers are receiving ART at 12 (and 24 months) postpartum |
| HIV.IND.42 Logic |
% of HIV-exposed infants whose final HIV outcome status is known |
| HIV.IND.43 Logic |
% of pregnant women who are HIV-positive at the time of their first test during the current pregnancy |
| HIV.IND.44 Logic |
Number and % of eligible people living with HIV on ART who initiated TB preventive treatment |
| HIV.IND.45 Logic |
Number and % of people living with HIV on ART who completed a course of TB preventive treatment among those who initiated TPT |
| HIV.IND.46 Logic |
% of people living with HIV with TB symptoms who receive a rapid molecular test, for example, Xpert MTB/RIF, as a first test for diagnosis of TB |
| HIV.IND.47 Logic |
% of people living with HIV newly initiated on ART who have active TB disease |
| HIV.IND.48 Logic |
% of people living with HIV newly initiated on ART who were screened for TB |
| HIV.IND.49 Logic |
% of people living with HIV newly initiated on ART who were screened for TB symptoms and who screened positive |
| HIV.IND.5 Logic |
Number of people prescribed PEP during the reporting period |
| HIV.IND.50 Logic |
% of people living with HIV newly initiated on ART and screened positive for TB symptoms who then are tested for TB |
| HIV.IND.51 Logic |
% of people living with HIV newly initiated on ART and tested for TB who are diagnosed with active TB disease |
| HIV.IND.52 Logic |
% of people living with HIV newly initiated on ART and diagnosed with active TB who initiated TB treatment |
| HIV.IND.53 Logic |
% of people living with HIV and On ART who are receiving multi-month dispensing of ARV medicine during the reporting period |
| HIV.IND.54 Logic |
% of people newly enrolled in DSD ART models among those eligible |
| HIV.IND.55 Logic |
% of people living with HIV enrolled in DSD ART models among those eligible for DSD ART (for facilities with electronic HIS) or among people living with HIV On ART (facilities with paper-based systems) during the reporting period |
| HIV.IND.56 Logic |
% of people retained in DSD ART models during the reporting period |
| HIV.IND.57 Logic |
% of people living with HIV engaged in DSD ART models who have virological suppression |
| HIV.IND.58 Logic |
% of people attending HIV prevention services who were tested for syphilis during the reporting period |
| HIV.IND.59 Logic |
% of people living with HIV who were tested for syphilis during the reporting period |
| HIV.IND.6 Logic |
% of PEP recipients completing PEP course |
| HIV.IND.60 Logic |
% of pregnant women who were tested for syphilis on first ANC services visit during the reporting period |
| HIV.IND.61 Logic |
% of pregnant women who were tested for syphilis on any ANC visit during the reporting period |
| HIV.IND.62 Logic |
% of people attending HIV prevention services who were tested for syphilis and had a positive syphilis test result during the reporting period |
| HIV.IND.63 Logic |
% of people living with HIV who were tested for syphilis and had a positive syphilis test result during the reporting period |
| HIV.IND.64 Logic |
% of pregnant women who tested positive for syphilis during first ANC services visit in the reporting period |
| HIV.IND.65 Logic |
% of pregnant women who tested positive for syphilis during the reporting period |
| HIV.IND.66 Logic |
% of people attending HIV prevention services tested positive for syphilis who were treated based on national guidelines during the reporting period |
| HIV.IND.67 Logic |
% of people living with HIV tested positive for syphilis who were treated based on national guidelines during the reporting period |
| HIV.IND.68 Logic |
% of pregnant women tested positive for syphilis on first ANC services visit who were treated based on national guidelines during the reporting period |
| HIV.IND.69 Logic |
% of pregnant women who tested positive for syphilis who were treated based on national guidelines during the reporting period |
| HIV.IND.7 Logic |
% of PEP recipients testing HIV-positive three months after PEP was prescribed |
| HIV.IND.70 Logic |
% of people attending HIV prevention services tested for gonorrhoea during the reporting period |
| HIV.IND.71 Logic |
% of people living with HIV tested for gonorrhoea during the reporting period |
| HIV.IND.72 Logic |
% of people who tested positive for gonorrhoea during the reporting period |
| HIV.IND.73 Logic |
% of people living with HIV who tested positive for gonorrhoea during the reporting period |
| HIV.IND.74 Logic |
% of people attending HIV prevention services tested positive for gonorrhoea who were treated based on national guidelines during the reporting period |
| HIV.IND.75 Logic |
% of people living with HIV tested positive for gonorrhoea who were treated based on national guidelines during the reporting period |
| HIV.IND.76 Logic |
% of people attending HIV prevention services diagnosed with a particular STI syndrome during the reporting period |
| HIV.IND.77 Logic |
% of people living with HIV diagnosed with a particular STI syndrome during the reporting period |
| HIV.IND.78 Logic |
% of people attending HIV prevention services diagnosed with a particular STI syndrome who were diagnosed with the same STI syndrome two or more times during the reporting period |
| HIV.IND.79 Logic |
% of people living with HIV diagnosed with a particular STI syndrome who were diagnosed with the same STI syndrome two or more times during the reporting period |
| HIV.IND.8 Logic |
% of people who inject drugs provided with needles-syringes during the reporting period |
| HIV.IND.80 Logic |
% of people attending HIV prevention services who were tested for hepatitis B surface antigen (HBsAg) during the reporting period (laboratory-based test or rapid test) |
| HIV.IND.81 Logic |
% of people living with HIV who were tested for hepatitis B surface antigen (HBsAg) during the reporting period (laboratory-based test or rapid test) |
| HIV.IND.82 Logic |
% of pregnant women who were tested for hepatitis B surface antigen (HBsAg) during the reporting period (laboratory-based test or rapid test) |
| HIV.IND.83 Logic |
% of people attending HIV prevention services who were tested for HCV (HCV antibody, HCV RNA or HCV core antigen) during the reporting period (laboratory-based test or rapid test) |
| HIV.IND.84 Logic |
% of people living with HIV who were tested for HCV (HCV antibody, HCV RNA or HCV core antigen) during the reporting period (laboratory-based test or rapid test) |
| HIV.IND.85 Logic |
Percentage of people attending HIV prevention services who were tested for HBsAg and had a positive HBsAg test during the reporting period |
| HIV.IND.86 Logic |
Percentage of people living with HIV who were tested for HBsAg and had a positive HBsAg test during the reporting period |
| HIV.IND.87 Logic |
Percentage of pregnant women who were tested for HBsAg and had a positive HBsAg test during the reporting period |
| HIV.IND.88 Logic |
% of people attending HIV prevention services with a positive HCV test result (HCV antibody, HCV RNA (PCR) or HCV core antigen) during the reporting period |
| HIV.IND.89 Logic |
% of people living with HIV with a positive HCV test result (HCV antibody, HCV RNA (PCR) or HCV core antigen) during the reporting period |
| HIV.IND.9 Logic |
% of people who inject drugs accessing a needle-syringe programme (NSP) at least once per month during the reporting period |
| HIV.IND.90 Logic |
% of people living with HIV and diagnosed with HBV infection who are on TDF-based ART |
| HIV.IND.91 Logic |
% of people living with HIV and diagnosed with HCV infection who initiated HCV treatment (direct acting antivirals) during the reporting period |
| HIV.IND.92 Logic |
% of people living with HIV and co-infected with HCV who were confirmed to be cured of HCV during the reporting period |
| HIV.IND.93 Logic |
Number of women living with HIV who were screened for cervical cancer using any screening test |
| HIV.IND.94 Logic |
% of women living with HIV who screened positive for pre-invasive cervical disease and received treatment for it |
| HIV.IND.95 Logic |
% of women living with HIV diagnosed with invasive cancer who were treated |
| HIV.IND.96 Logic |
Crude probability of surviving 1 year after a diagnosis of cervical cancer |
| HIVCommon |
Description not yet available for HIVCommon. |
| HIVConcepts |
Description not yet available for HIVConcepts. |
| HIVConceptsCustom |
Description not yet available for HIVConceptsCustom. |
| HIVConfig |
Description not yet available for HIVConfig. |
| HIVElements |
Description not yet available for HIVElements. |
| HIVEncounterElements |
Description not yet available for HIVEncounterElements. |
| HIVIndicatorElements |
Description not yet available for HIVIndicatorElements. |
| WHOCommon |
Description not yet available for WHOCommon. |
| WHOConcepts |
Description not yet available for WHOConcepts. |
| WHOElements |
Description not yet available for WHOElements. |
| WHOEncounterElements |
Description not yet available for WHOEncounterElements. |
These define data models that represent the domain covered by this implementation guide in more business-friendly terms than the underlying FHIR resources.
| HIV.A Registration |
This tab describes the data that are collected during the registration workflow (HIV.A) |
| HIV.B HTS visit |
This tab describes the data that are collected during the HIV Testing services visit workflow (HIV.B) |
| HIV.C PrEP visit |
This tab describes the data that may be collected during the pre-exposure prophylaxis (PrEP) or post-exposure prophylaxis (PEP) workflow (HIV.C) |
| HIV.Configuration |
This tab describes data about a facility or region that are used in workflows and decision logic (i.e. WHO recommendations depend upon these data elements), but are not specific to an individual (e.g. a high HIV burden setting) |
| HIV.D Care-Treatment |
This tab describes the data that may be collected during care and treatment clinical visit for HIV workflow (HIV.D) |
| HIV.D HIV-TB |
This tab describes the data that may be collected during care and treatment clinical visit for HIV/TB care (HIV.D) |
| HIV.E-F PMTCT |
This tab describes the data that are collected relevant to HIV care and treatment of pregnant and postpartum women and their newborns during the delivery and postpartum care and the infant diagnosis and final HIV status workflows (HIV.E and HIV.F) |
| HIV.G Diagnostics |
This tab describes the data that are collected during the workflow for diagnostics for HIV (HIV.G) |
| HIV.H Follow-up |
This tab describes the data that are collected during the follow-up and contacting clients workflow (HIV.H) |
| HIV.I Referral |
This tab describes the data that are collected during the referral workflow (HIV.I) |
| HIV.Prevention |
This tab describes the data that are collected during HIV prevention activities (not covered in the previous business processes) |
| HIV.Surveillance |
This tab describes the data that are collected during case surveillance (these data elements are drawn from other tabs and do not include data element IDs). |
These define forms used by systems conforming to this implementation guide to capture or expose data to end users.
| Assess for vaccine-preventable diseases |
Questionnaire for assess for vaccine-preventable diseases |
| Attempt to locate client |
Questionnaire for attempt to locate client |
| Capture or update client history |
Questionnaire for capture or update client history |
| Capture or update client history |
Questionnaire for capture or update client history |
| Capture or update client history |
Questionnaire for capture or update client history |
| Capture or update infant's/child's history |
Questionnaire for capture or update infant's/child's history |
| Capture or update mother's history |
Questionnaire for capture or update mother's history |
| Check for signs of serious illness |
Questionnaire for check for signs of serious illness |
| Check for signs of treatment failure |
Questionnaire for check for signs of treatment failure |
| Check whether infant/child had HIV exposure |
Questionnaire for check whether infant/child had HIV exposure |
| Counsel |
Questionnaire for counsel |
| Counsel on risk and prevention |
Questionnaire for counsel on risk and prevention |
| Counsel returning client |
Questionnaire for counsel returning client |
| Create new client record |
Questionnaire for create new client record |
| Determine clinical stage of HIV |
Questionnaire for determine clinical stage of HIV |
| Determine reason for visit |
Questionnaire for determine reason for visit |
| Determine reason for visit |
Questionnaire for determine reason for visit |
| Determine reason for visit |
Questionnaire for determine reason for visit |
| Determine recommended screenings and tests |
Questionnaire for determine recommended screenings and tests |
| Determine recommended services |
Questionnaire for determine recommended services |
| Determine recommended tests |
Questionnaire for determine recommended tests |
| Determine regimen and treatment options |
Questionnaire for determine regimen and treatment options |
| Diagnostics |
Questionnaire for diagnostics |
| Diagnostics |
Questionnaire for diagnostics |
| Emergency referral? |
Questionnaire for emergency referral? |
| Following up and contacting clients |
Questionnaire for following up and contacting clients |
| Gather client details |
Questionnaire for gather client details |
| Identify client for follow-up |
Questionnaire for identify client for follow-up |
| Immediately start infant on ART |
Questionnaire for immediately start infant on ART |
| Offer other services |
Questionnaire for offer other services |
| Offer prevention options |
Questionnaire for offer prevention options |
| Offer sexual and reproductive health services |
Questionnaire for offer sexual and reproductive health services |
| Offer sexual and reproductive health services |
Questionnaire for offer sexual and reproductive health services |
| Offer voluntary partner and family services |
Questionnaire for offer voluntary partner and family services |
| Perform other screenings |
Questionnaire for perform other screenings |
| Post-test package of services |
Questionnaire for post-test package of services |
| Prescribe |
Questionnaire for prescribe |
| Prescribe |
Questionnaire for prescribe |
| Prescribe or administer PrEP or PEP |
Questionnaire for prescribe or administer PrEP or PEP |
| Prevent, screen, and manage comorbidities and coinfections |
Questionnaire for prevent, screen, and manage comorbidities and coinfections |
| Provide information to referral facility |
Questionnaire for provide information to referral facility |
| Provide post-test counselling |
Questionnaire for provide post-test counselling |
| Provide voluntary partner and family services |
Questionnaire for provide voluntary partner and family services |
| Record infant's/child's final HIV diagnosis |
Questionnaire for record infant's/child's final HIV diagnosis |
| Record outreach and result |
Questionnaire for record outreach and result |
| Review sociodemographic data with client |
Questionnaire for review sociodemographic data with client |
| Schedule follow-up |
Questionnaire for schedule follow-up |
| Schedule follow-up |
Questionnaire for schedule follow-up |
| Schedule retest |
Questionnaire for schedule retest |
| Screen for TB |
Questionnaire for screen for TB |
| Suitable for PrEP or PEP? |
Questionnaire for suitable for PrEP or PEP? |
| Take vital signs |
Questionnaire for take vital signs |
| Take vital signs |
Questionnaire for take vital signs |
| Test for HIV using testing algorithm |
Questionnaire for test for HIV using testing algorithm |
| Test infant/child for HIV using testing algorithm |
Questionnaire for test infant/child for HIV using testing algorithm |
| Test mother for HIV using testing algorithm |
Questionnaire for test mother for HIV using testing algorithm |
These define constraints on FHIR resources for systems conforming to this implementation guide.
| Alternative PEP Backbone Prescription |
A profile for MedicationRequest representing an alternative PEP backbone prescription. |
| Alternative Third PEP Prescription |
A profile for MedicationRequest representing an alternative Third PEP drug choice prescription. |
| Current PrEP Regimen Prescription |
A profile for MedicationRequest representing a prescription of a current PrEP regimen. |
| Elevated HIV Risk Acquisition Condition |
A condition identifying patients at elevated risk for HIV acquisition. |
| HIV Prep Active |
A medication statement describing a patient on active PrEP |
| HIV Status Condition |
A condition representing a patient's HIV status. |
| HIV Status Observation |
An observation representing a patient's HIV status. |
| HIV Test |
An DAK-specific HIV test observation with possible results |
| HivPatient | |
| On ART Medication Statement |
A medication statement describing a Patient's ART program |
| Patient Key Population Status |
An observation describing Patient's key population status |
| PrEP Product Prescription |
A profile for MedicationRequest representing a prescription of a PrEP product. |
| Preferred PEP Backbone Prescription |
A profile for MedicationRequest representing a preferred PEP backbone prescription. |
| Preferred Third PEP Prescription |
A profile for MedicationRequest representing the preferred third PEP drug choice prescription. |
These define sets of codes used by systems conforming to this implementation guide.
| ART regimen ValueSet |
Value set of list of ART regimens |
| ART regimen composition ValueSet |
Value set of drug composition of client's current ART regimen |
| ART regimen drug class ValueSet |
Value set of drug class of current ART regimen |
| ART regimen prescribed ValueSet |
Value set of iNCLUDE VALUE SETS OF REGIMENS |
| ART start type ValueSet |
Value set of whether the client is ART naive or is restarting ART |
| ARV drug regimen received prior to enrolment ValueSet |
Value set of aRV drug regimen received prior to enrolment into HIV care/ART |
| Acute HIV infection symptoms ValueSet |
Value set of symptoms that could suggest an acute HIV infection |
| Administrative Area ValueSet |
Value set of this should be a context-specific list of administrative areas, such as villages, districts, etc. The purpose of this data element is to allow for grouping and flagging of client data to a particular facility's catchment area. This can be input into the system by the end user OR it can be automated in the database based on the end user's attributes. |
| Adverse event severity ValueSet |
Value set of severity of the adverse event associated with voluntary medical male circumcision (VMMC) procedure |
| Allergies ValueSet |
Value set of does the client have any allergies? |
| Alternative PEP backbone regimen ValueSet |
Value set of alternative backbone regimen for PEP |
| Alternative first-line ART regimen ValueSet |
Value set of the alternative first-line ART regimen for the client according to WHO (or national) guidelines |
| Alternative second-line ART regimen ValueSet |
Value set of the alternative second-line ART regimen for the client according to WHO (or national) guidelines |
| Alternative third PEP drug ValueSet |
Value set of alternative third drug for PEP |
| Antiretroviral (ARV) drugs received prior to enrolment ValueSet |
Value set of whether or not the client received ARV drugs prior to enrolling into HIV care |
| Assay number in testing strategy ValueSet |
Value set of the number of the assay (test kit) in the HIV testing strategy |
| Assay number in testing strategy ValueSet |
Value set of the number of the assay (test kit) in the HIV testing strategy |
| Asymptomatic bacteriuria (ASB) test result ValueSet |
Value set of result of urine culture (or urine Gram-staining if not available over dipstick tests) for diagnosing asymptomatic bacteriuria |
| Blood group and Rh factor ValueSet |
Value set of mother's blood type and blood Rh factor |
| Cause of death of infant ValueSet |
Value set of the infant's cause of death |
| Cause of death of mother ValueSet |
Value set of the woman's cause of death |
| Cervical cancer colposcopy result ValueSet |
Value set of result of cervical cancer colposcopy |
| Cervical cancer diagnosis ValueSet |
Value set of type of cervical cancer diagnosis |
| Cervical cancer histopathology result ValueSet |
Value set of result of cervical cancer histopathology |
| Cervical cancer primary screening test type ValueSet |
Value set of type of cervical cancer screening test used in primary screening |
| Cervical cancer screening outcome ValueSet |
Value set of client's screening outcome for cervical cancer |
| Cervical cancer stage at diagnosis ValueSet |
Value set of cervical cancer stage at diagnosis of cervical cancer |
| Cervical cancer triage test type ValueSet |
Value set of type of triage test for cervical cancer |
| Cervical cytology screening test result ValueSet |
Value set of screening result for cervical cytology |
| Chlamydia trachomatis test type ValueSet |
Value set of type of diagnostic test used for Chlamydia trachomatis |
| Chlamydia trachomatis test type ValueSet |
Value set of type of diagnostic test used for Chlamydia trachomatis |
| Clinical stage at start of ART ValueSet |
Value set of wHO clinical stage of client based on signs and symptoms at start of ART |
| Coinfection status at ART start ValueSet |
Value set of clients status of coinfections at the time when ART was initiated |
| Communication preference(s) ValueSet |
Value set of how the client would like to receive family planning communications |
| Condom type ValueSet |
Value set of type of condom provided to client |
| Confirmatory STI test result ValueSet |
Value set of result from confirmatory STI test |
| Confirmatory STI test result ValueSet |
Value set of result from confirmatory STI test |
| Confirmatory syphilis test type ValueSet |
Value set of type of test ued for confirmatory syphilis test |
| Confirmatory syphilis test type ValueSet |
Value set of type of test ued for confirmatory syphilis test |
| Contact method ValueSet |
Value set of method used to try to reach out to the client |
| Contraindications to PrEP usage ValueSet |
Value set of listing of contraindications to pre-exposure prophylaxis (PrEP) |
| Counselling provided ValueSet |
Value set of whether counselling was provided to a client during the visit |
| Country of birth ValueSet |
Value set of country where the client was born |
| Current ART regimen (first-, second-, or third-line) ValueSet |
Value set of aRT regimen for treating clients living with HIV, based on national guidance |
| Current ART regimen ValueSet |
Value set of the current ART regimen the client is taking |
| Current PrEP regimen ValueSet |
Value set of HIV pre-exposure prophylaxis (PrEP) regimen |
| Current medications ValueSet |
Value set of list of all of the medications the client is currently taking |
| DSD ART model(s) ValueSet |
Value set of type of DSD ART model client is enrolled in (country-specific) |
| Delivery mode ValueSet |
Value set of mode of delivery for current pregnancy |
| Disease targeted ValueSet |
Value set of vaccine preventable disease being targeted by vaccine administered |
| EID sample number ValueSet |
Value set of early infant diagnosis (EID) sample number |
| EID test number 1 test result ValueSet |
Value set of early infant diagnosis test number 1 test result |
| EID test number 2 test result ValueSet |
Value set of early infant diagnosis test number 2 test result |
| EID test number ValueSet |
Value set of early infant diagnosis (EID) HIV test number using the same sample |
| Entry point for community-level testing ValueSet |
Value set of specific point in the community where testing is happening |
| Entry point for facility-level testing ValueSet |
Value set of specific point where testing is happening at a facility |
| Entry point for facility-level testing ValueSet |
Value set of specific point where testing is happening at a facility |
| Existing chronic health conditions ValueSet |
Value set of does the client have any current chronic health conditions or problems? |
| Experience with PrEP ValueSet |
Value set of the client's experience in taking PrEP |
| Facility transferred from ValueSet |
Value set of name of health facility client was transferred from |
| Facility where client first enrolled in HIV care ValueSet |
Value set of facility where the client first enrolled in HIV care |
| Family planning method used ValueSet |
Value set of method the client reports currently using at intake |
| Final diagnosis of HIV-exposed infant ValueSet |
Value set of HIV-exposed infant final status at 18 months or 3 months after cessation of breastfeeding (whichever is later). |
| First-line ART regimen under special circumstances ValueSet |
Value set of the first-line ART regimen for the client under special circumstances according to WHO (or national) guidelines |
| Gender ValueSet |
Value set of gender of the client |
| Gender of infant ValueSet |
Value set of gender of the infant |
| General care activities recommended ValueSet |
Value set of general care activities to be performed during the care visit |
| Gonorrhoea test result ValueSet |
Value set of result from Gonorrhoea test |
| Gonorrhoea test result ValueSet |
Value set of result from Gonorrhoea test |
| HBV treatment regimen prescribed ValueSet |
Value set of hepatitis B virus treatment regimen prescribed |
| HBsAg test result ValueSet |
Value set of hepatitis B virus test result (HBsAg) |
| HBsAg test result ValueSet |
Value set of hepatitis B virus test result (HBsAg) |
| HCV medicine type ValueSet |
Value set of type of medicine client is prescribed |
| HCV test result ValueSet |
Value set of hepatitis C virus test result (HCV antibody, HCV RNA or HCV core antigen) |
| HCV test result ValueSet |
Value set of hepatitis C virus test result (HCV antibody, HCV RNA or HCV core antigen) |
| HCV treatment regimen prescribed ValueSet |
Value set of hepatitis C virus treatment regimen prescribed |
| HCV viral load test result ValueSet |
Value set of hepatitis C viral load test result (qualitative) |
| HCV viral load test result ValueSet |
Value set of hepatitis C viral load test result (qualitative) |
| HIV burden of the setting ValueSet |
Value set of HIV burden of the setting (high or low) based on the national HIV prevalence or where the HIV prevalence and/or incidence in a geographical setting is higher than national prevalence and, therefore, needs priority in the HIV response |
| HIV clinical stage ValueSet |
Value set of wHO clinical stage of client based on signs and symptoms. WHO clinical staging is a way to categorize HIV disease severity based on new or recurrent clinical events. There are 4 WHO clinical stages that range from mild symptoms (WHO clinical stage 1) to severe symptoms (WHO clinical stage 4). |
| HIV diagnosing facility ValueSet |
Value set of the facility where the client received an HIV-positive diagnosis |
| HIV exposure type ValueSet |
Value set of ways in which the client was exposed to HIV |
| HIV prevention intervention ValueSet |
Value set of HIV prevention intervention that client accessed |
| HIV self-test distributed for use by ValueSet |
Value set of whom the client plans to give the HIV self-test kit (self, sexual partner, social contact, etc.) |
| HIV self-test result ValueSet |
Value set of results from the reported HIV self-test |
| HIV serotype ValueSet |
Value set of the client's HIV serotype |
| HIV status ValueSet |
Value set of HIV status reported after applying the national HIV testing algorithm. No single HIV test can provide an HIV-positive diagnosis. |
| HIV status of contact ValueSet |
Value set of the HIV status of the client's contact |
| HIV status of family member ValueSet |
Value set of HIV status of each family member at time of patient's enrolment, including partner (for mothers) |
| HIV status of partner or contact ValueSet |
Value set of HIV status of the partner or contact given by the index case |
| HIV test result ValueSet |
Value set of the result from HIV testing after applying the testing algorithm |
| HIV test type ValueSet |
Value set of type of HIV test |
| HIV test type ValueSet |
Value set of type of HIV test |
| HIV treatment outcome ValueSet |
Value set of the outcome for the client which is used for reporting retention/attrition. |
| HIV viral load specimen type ValueSet |
Value set of the type of specimen to be used to test viral load |
| HIV-exposed infant reason for unknown final status ValueSet |
Value set of the outcome for the infant does not have a final outcome, which may because of death, stopped treatment or lost to follow-up. |
| HPV-DNA cervical cancer screening test result ValueSet |
Value set of hPV-DNA cervical cancer screening test result |
| HPV16/18 test result ValueSet |
Value set of test result from HPV16/18 test |
| Hepatitis B diagnosis ValueSet |
Value set of client's hepatitis B diagnosis |
| Hepatitis C diagnosis ValueSet |
Value set of client's hepatitis C diagnosis |
| Herpes simplex virus (HSV) test type ValueSet |
Value set of type of diagnostic test used for herpes simplex virus (HSV) |
| Herpes simplex virus (HSV) test type ValueSet |
Value set of type of diagnostic test used for Herpes simplex virus (HSV) |
| Infant HIV status ValueSet |
Value set of HIV status reported after applying the HIV testing algorithm. No single HIV test can provide an HIV-positive diagnosis. |
| Infant feeding practice ValueSet |
Value set of infant feeding practice |
| Infant or child exposure to HIV ValueSet |
Value set of whether the infant or child was determined to have had HIV exposure through mother |
| Intimate partner violence enquiry results ValueSet |
Value set of result of medical inquiry for intimate partner violence |
| Invasive cervical cancer treatment method ValueSet |
Value set of invasive cervical cancer treatment method |
| Key population member type ValueSet |
Value set of the type of key population that the client is included in |
| Key population member type ValueSet |
Value set of the type of key population that the infant's mother is included in |
| Location ARV drugs received prior to enrolment ValueSet |
Value set of health facility (or other location) where ARV drugs were received prior to enrolment into HIV care/ART |
| Marital Status ValueSet |
Value set of client's current marital status |
| Maternal HIV status ValueSet |
Value set of the HIV status of the infant's mother |
| Maternal HIV status at first ANC visit ValueSet |
Value set of the HIV status of the infant's mother at first ANC visit |
| Maternal HIV test result ValueSet |
Value set of test result for mother after applying the testing strategy |
| Maternal and child health service visit ValueSet |
Value set of maternal and child health service visit attended by an HIV-exposed infant |
| Maternal syphilis test result ValueSet |
Value set of result from maternal syphilis test |
| Medication status ValueSet |
Value set of current state of the client's taking of the medication |
| Medication/drug ValueSet |
Value set of current or considered medication/drug, for the purpose of determining drug interactions |
| Medications dispensed ValueSet |
Value set of any other medications that were dispensed to client, including preventive treatment |
| Medications prescribed ValueSet |
Value set of medications the client was prescribed |
| Medications prescribed ValueSet |
Value set of name or regimen code of all other medications prescribed during the visit |
| Method of TB diagnosis ValueSet |
Value set of method used to set the TB diagnosis |
| Monitoring examinations ValueSet |
Value set of name of examinations, test and results for any relevant investigations carried out for client |
| Mycoplasma genitalium test type ValueSet |
Value set of type of diagnostic test used for Mycoplasma genitalium |
| Mycoplasma genitalium test type ValueSet |
Value set of type of diagnostic test used for Mycoplasma genitalium |
| Neisseria gonorrhoeae test type ValueSet |
Value set of type of diagnostic test used for Neisseria gonorrhoeae |
| Neisseria gonorrhoeae test type ValueSet |
Value set of type of diagnostic test used for Neisseria gonorrhoeae |
| New antiretroviral regimen after substitution within first-line regimen ValueSet |
Value set of new antiretroviral (ARV) drugs after client changed regimen within the first-line regimen |
| New regimen after switch to second-line regimen ValueSet |
Value set of new ART regimen after switch to second-line ART regimen |
| New regimen after switch to third-line regimen ValueSet |
Value set of new ART regimen after switch to third-line ART regimen |
| New regimen(s) after substitution within second-line regimen ValueSet |
Value set of new ARV drugs after client changed regimen within the second- line regimen |
| New regimen(s) after substitution within third-line regimen ValueSet |
Value set of new ARV drugs after client changed regimen within the third-line regimen |
| Offer other clinical services ValueSet |
Value set of other clinical services offered or referrals given to the client |
| Offer other clinical services ValueSet |
Value set of other clinical services offered or referrals given to the client |
| Offer other clinical services ValueSet |
Value set of other clinical services offered or referrals given to the client |
| Optimal regimen for transition ValueSet |
Value set of the optimal regimen for transition to DTG-based regimens for children established on ART |
| Original first-line ART regimen ValueSet |
Value set of original full, first-line ARV drug regimen patient started on at this facility |
| Other priority populations ValueSet |
Value set of other populations of priority of HIV prevention and care in local context (provided during adaptation) |
| Other support services ValueSet |
Value set of offer or refer for other support services |
| Other support services ValueSet |
Value set of offer or refer for other support services |
| Other support services ValueSet |
Value set of offer or refer for other support services |
| Outcome from outreach attempt ValueSet |
Value set of detailed outcome from the attempt to locate the client |
| PEP history ValueSet |
Value set of the client's history in taking post-exposure prophylaxis (PEP) for HIV prevention |
| Partner HIV status (confirmed) ValueSet |
Value set of the HIV status of a sexual or drug-injecting partner of the client, based on a confirmed test result |
| Partner HIV status (reported) ValueSet |
Value set of the HIV status of the client's partner. |
| Partner HIV test result ValueSet |
Value set of the HIV test result of the client's partner |
| Partner is from a key population ValueSet |
Value set of client's partner is a member of a key population, that has an increased risk of HIV |
| Past pregnancy complications ValueSet |
Value set of whether the woman has had any complications or problems in any previous pregnancy |
| Place of delivery ValueSet |
Value set of the type of place where the woman delivered |
| PrEP dosing type ValueSet |
Value set of way in which pre-exposure prophylaxis (PrEP) is taken (daily or event-driven) |
| PrEP product prescribed ValueSet |
Value set of prEP product that the client was prescribed |
| PrEP regimen prescribed ValueSet |
Value set of HIV pre-exposure prophylaxis (PrEP) regimen prescribed |
| Preferred PEP backbone regimen ValueSet |
Value set of preferred backbone regimen for PEP |
| Preferred first-line ART regimen ValueSet |
Value set of the preferred first-line ART regimen for the client according to WHO (or national) guidelines |
| Preferred second-line ART regimen ValueSet |
Value set of the preferred second-line ART regimen for the client according to WHO (or national) guidelines |
| Preferred third PEP drug ValueSet |
Value set of preferred third drug for PEP |
| Pregnancy intention in serodiscordant partnerships ValueSet |
Value set of client's intention or desire in the next year to either become pregnant or prevent a future pregnancy (in serodiscordant partnerships) |
| Pregnancy outcome ValueSet |
Value set of outcome of current pregnancy |
| Pregnant and breastfeeding status at ART start ValueSet |
Value set of aRT status of women to prevent mother-to-child transmission |
| Preterm birth status ValueSet |
Value set of the woman gave birth when the gestational age is less than 37 weeks |
| Preventing and treating coinfections ValueSet |
Value set of coinfection prevention and treatment activities performed during the care visit |
| Prevention services offered and referrals ValueSet |
Value set of offer or refer to prevention services |
| Prevention services offered and referrals ValueSet |
Value set of offer or refer to prevention services |
| Prevention services offered and referrals ValueSet |
Value set of offer or refer for prevention services |
| Probable route of transmission ValueSet |
Value set of probable route(s) of transmission of HIV to client |
| Reason ART stopped ValueSet |
Value set of reason client intentionally stopped ART |
| Reason ART stopped ValueSet |
Value set of reason why client intentionally stopped ART |
| Reason Hepatitis B test not conducted ValueSet |
Value set of reason why a hepatitis B test was not done |
| Reason Hepatitis C test not done ValueSet |
Value set of reason why a hepatitis C test was not done |
| Reason blood pressure reading not done ValueSet |
Value set of reason why test was not performed |
| Reason for ARV drug regimen substitution ValueSet |
Value set of reason why a substitution was made to the antiretroviral (ARV) drug regimen |
| Reason for HIV viral load test ValueSet |
Value set of whether the viral load is being tested for routine monitoring on a set schedule or for targeted monitoring for suspected treatment failure |
| Reason for PrEP visit ValueSet |
Value set of client's reason for the prevention visit |
| Reason for follow-up ValueSet |
Value set of the reason why the client is being followed up |
| Reason for referral ValueSet |
Value set of reason why the client is being referred. If diagnosed, this may include the reason for the diagnosis. |
| Reason for regimen switch ValueSet |
Value set of reason why a switch to a second- or third-line regimen was made |
| Reason for switch to second-line regimen ValueSet |
Value set of reason why client was switched from first- to second-line ARV drug regimen (see 'Reason for regimen switch' for levels) |
| Reason for switch to third-line regimen ValueSet |
Value set of reason why client was switched from second- to third-line ARV drug regimen (see 'Reason for regimen switch' for levels) |
| Reason for visit ValueSet |
Value set of reason for HIV testing services visit |
| Reason for visit ValueSet |
Value set of whether visit was scheduled or unscheduled, clinical only, or for ARV drug pick-up |
| Reason immunization was not provided ValueSet |
Value set of reason the vaccine dose was not given |
| Reason malaria prophylaxis not provided ValueSet |
Value set of reason why the treatment was not given |
| Reason syphilis test not done ValueSet |
Value set of reason why a syphilis test was not done |
| Reason(s) for adherence problem ValueSet |
Value set of reason why client was not adherent |
| Reason(s) for adherence problem ValueSet |
Value set of reason why client is not adherent |
| Reason(s) for substitution within first-line regimen ValueSet |
Value set of reason(s) why one ore more drugs in client's first-line ARV drug regimen was changed (substituted) |
| Reason(s) for substitution within second-line regimen ValueSet |
Value set of reason(s) why client changed drug regimen (within the second-line) |
| Reason(s) for substitution within third-line regimen ValueSet |
Value set of reason(s) why client changed drug regimen (within the third-line) |
| Reasons for delayed ART initiation ValueSet |
Value set of reason why ART was not initiated at diagnosis or within 7 days of diagnosis |
| Referred by ValueSet |
Value set of how the client was referred |
| Referred through partner services ValueSet |
Value set of client reported coming to the facility after receiving a provider-assisted referral or patient referral from a contact or partner |
| Risk factors, comorbidities and coinfections signs and symptoms ValueSet |
Value set of signs and symptoms of opportunistic infections or other comorbidities experienced by client |
| STI test result ValueSet |
Value set of result from STI test |
| STI test result ValueSet |
Value set of result from STI test |
| STI tested for ValueSet |
Value set of sTI for which the client was tested |
| STI tested for ValueSet |
Value set of sTI for which the client was tested |
| Screenings and diagnostics for PrEP users ValueSet |
Value set of listing of tests for clients on or starting pre-exposure prophylaxis (PrEP) that may be recommended or should be considered |
| Sex ValueSet |
Value set of sex of the client assigned at birth |
| Sex factor for estimating creatinine clearance ValueSet |
Value set of value used for gender for calculating creatinine clearance if required. For transgender populations, the sex at birth is used in the Cockcroft-Gault equation if the person is not using hormone therapy; among transgender populations using hormone therapy for more than three months, the current gender can be used. |
| Sex partner's HIV treatment status ValueSet |
Value set of treatment adherence of client's sex partner for partners that are HIV-positive |
| Sexual and reproductive health integrated services ValueSet |
Value set of offer or refer to sexual and reproductive health services |
| Sexual and reproductive health integrated services ValueSet |
Value set of offer or refer to sexual and reproductive health services |
| Sexual and reproductive health integrated services ValueSet |
Value set of offer or refer to sexual and reproductive health services |
| Signs of serious illness ValueSet |
Value set of signs that may indicate the client has a serious illness and needs triage or an emergency referral |
| Signs of substantial risk of HIV infection ValueSet |
Value set of signs the client is at a substantial risk of HIV infection |
| Signs of substantial risk of HIV infection ValueSet |
Value set of signs the client is at a substantial risk of HIV infection |
| Site where positive HIV test confirmed ValueSet |
Value set of name or identifier of health facility where HIV test was confirmed |
| Source of gestational age ValueSet |
Value set of gestational age can be calculated multiple ways. This data element describes where the gestational age above has been calculated from. |
| Source of information ValueSet |
Value set of source of information about the client |
| Staging of liver disease ValueSet |
Value set of staging of liver disease in client |
| Symptoms of TB ValueSet |
Value set of symptoms that may indicate TB disease in clients living with HIV, based on a clinical algorithm |
| Syndrome/STI diagnosed ValueSet |
Value set of syndrome or STI for which client is diagnosed |
| Syndrome/STI diagnosed ValueSet |
Value set of syndrome or STI for which client is diagnosed |
| Syphilis diagnosis ValueSet |
Value set of client's syphilis diagnosis |
| Syphilis test result ValueSet |
Value set of result from syphilis test |
| Syphilis test result ValueSet |
Value set of result from syphilis test |
| Syphilis test result ValueSet |
Value set of result from syphilis test |
| Syphilis test type ValueSet |
Value set of type of diagnostic test used for syphilis (treponema pallidum) |
| Syphilis test type ValueSet |
Value set of type of diagnostic test used for syphilis (Treponema pallidum) |
| Syphilis test type ValueSet |
Value set of type of diagnostic test used for syphilis (treponema pallidum) |
| TB diagnosis result ValueSet |
Value set of final result of the TB investigation (bacteriological and/or clinical) |
| TB diagnostic test category ValueSet |
Value set of the type of diagnostic test performed to detect tuberculosis (TB) disease |
| TB preventive treatment (TPT) status ValueSet |
Value set of indicates the current status of TB preventive treatment (TPT) |
| TB screening algorithm ValueSet |
Value set of screening algorithm selected for screening activities |
| TB screening result ValueSet |
Value set of record the result of the tuberculosis (TB) screening |
| TB status at ART start ValueSet |
Value set of client's tuberculosis (TB) status when antiretroviral therapy (ART) is started |
| TB treatment history ValueSet |
Value set of history of previous TB treatment |
| TB treatment outcome ValueSet |
Value set of indicates patient's TB treatment outcome |
| TB treatment regimen composition ValueSet |
Value set of tB drugs currently being taken by the client |
| TPT regimen type ValueSet |
Value set of type of TPT regimen the client is currently on |
| Test result of HIV assay 1 ValueSet |
Value set of the result of the first HIV assay in the testing strategy |
| Test result of HIV assay 1 ValueSet |
Value set of the result of the first HIV assay in the testing strategy |
| Test result of HIV assay 1 repeated ValueSet |
Value set of the result of the repeated first HIV assay in the testing strategy |
| Test result of HIV assay 1 repeated ValueSet |
Value set of the result of the repeated first HIV assay in the testing strategy |
| Test result of HIV assay 2 ValueSet |
Value set of the result of the second HIV assay in the testing strategy |
| Test result of HIV assay 2 ValueSet |
Value set of the result of the second HIV assay in the testing strategy |
| Test result of HIV assay 3 ValueSet |
Value set of the result of the third HIV assay in the testing strategy |
| Test result of HIV assay 3 ValueSet |
Value set of the result of the third HIV assay in the testing strategy |
| Test result of syphilis assay 1 ValueSet |
Value set of the result of the first syphilis assay in the testing strategy |
| Test result of syphilis assay 1 repeated ValueSet |
Value set of the result of the first syphilis assay repeated in the testing strategy |
| Testing entry point ValueSet |
Value set of whether testing is happening in the community or at a facility |
| Time to start ART ValueSet |
Value set of time from HIV diagnosis to when client started ART |
| Timing of ART initiation ValueSet |
Value set of when the pregnant woman or mother initiated ART, for women living with HIV. |
| Timing of adverse event ValueSet |
Value set of when the adverse event associated with VMMC procedure occurred |
| Transfer to facility ValueSet |
Value set of name of health facility client was transferred to |
| Treatment failure ValueSet |
Value set of aRT treatment failure |
| Treatment method for cervical precancer lesions ValueSet |
Value set of treatment method for cervical precancer lesions |
| Trichomonas vaginalis test type ValueSet |
Value set of type of diagnostic test used for Trichomonas vaginalis |
| Trichomonas vaginalis test type ValueSet |
Value set of type of diagnostic test used for Trichomonas vaginalis |
| Type of adverse VMMC event ValueSet |
Value set of type of adverse event associated with voluntary medical male circumcision (VMMC) procedure |
| Type of contact elicited ValueSet |
Value set of client's relationship to the contact identified for voluntary partner services or family services |
| Type of contact or partner for partner services ValueSet |
Value set of client's relationship to the person that referred the client for partner services or family services |
| Type of follow-up appointment ValueSet |
Value set of type of follow-up appointment for testing services |
| Type of follow-up appointment ValueSet |
Value set of type of follow-up appointment for testing services |
| Type of follow-up appointment ValueSet |
Value set of whether the visit will be clinical only, ARV drug pick-up or other. Client may have multiple follow-ups scheduled. |
| Type of hypertensive disorder ValueSet |
Value set of type of hypertensive disorder of the mother |
| Type of iron supplement dosage provided ValueSet |
Value set of whether the amount of iron prescribed is for daily or weekly intake |
| Type of specimen ValueSet |
Value set of type of specimen to be collected |
| Type of specimen ValueSet |
Value set of type of specimen to be collected |
| Type of treatment-limiting toxicity ValueSet |
Value set of type of treatment-limiting toxicity experienced by client. Treatment-limiting toxicity is defined as a serious adverse drug reaction that results in drug discontinuation or substitution. In addition, any reaction that leads to treatment interruption or requires changing the drug or regimen because of an adverse drug reaction is also considered a serious adverse drug reaction. |
| Urine protein test result ValueSet |
Value set of results of urine protein test of mother during ANC visit |
| VIA cervical cancer screening test result ValueSet |
Value set of screening test result for VIA |
| Vaccination location ValueSet |
Value set of the service delivery location where the vaccine adminstration occurred |
| Vaccine brand ValueSet |
Value set of the brand or trade name used to refer to the vaccine received |
| Vaccine type ValueSet |
Value set of type of vaccine received (such as IPV, OPV) |
| WHO HIV clinical stage condition or symptom ValueSet |
Value set of new or recurrent clinical events used to categorize HIV disease severity based at baseline and follow up |
| WHO HIV clinical stage condition or symptom ValueSet |
Value set of new or recurrent clinical events used to categorize HIV disease severity based at baseline and follow up |
| WHO functional status ValueSet |
Value set of functional status of people with advanced HIV disease |
These define new code systems used by systems conforming to this implementation guide.
| WHO SMART HIV Concepts CodeSystem |
This code system defines the concepts used in the World Health Organization SMART HIV DAK |
These are example instances that show what data produced and consumed by systems conforming with this implementation guide might look like.
| Aggregate reporting and data use |
Functional Requirements For Aggregate reporting and data use |
| Care and treatment clinical visit |
Functional Requirements For Care and treatment clinical visit |
| Client |
In the context of this document, a client is a person who is given medical care, which may include HIV prevention, care or treatment services. Clients may be HIV-positive or HIV-negative, or they may not know their HIV status. A client living with HIV may be enrolled to receive antiretroviral treatment (ART) and/or other HIV-related treatment and care. |
| Community health worker |
A person who provides health education, referral and follow-up, case management and basic preventive health care and home visiting services to specific communities. Examples of HIV services that they provide include HIV testing, distributing HIV self-test (HIVST) kits, counselling in the community, monitoring adherence to ART and pre-exposure prophylaxis (PrEP) and drug pick- up, and following up and tracing lost patients. The occupation normally requires formal or informal training and supervision required by the health and social services authorities. |
| Data entry clerk |
An individual who helps to record, organize, store, compute and retrieve information, including patient records and registers. The knowledge and skills required are usually obtained through on- the-job training but may include post-secondary education. Clerks may also transcribe data, tally data, fill in routine reports and review the quality of data with others. |
| Diagnostics |
Functional Requirements For Diagnostics |
| District health information officer |
A manager supervising the monitoring system to track quality of care and data. This person provides a link between the health centre and central level to ensure that patient monitoring needs are met (for example, adequate staffing, tools and other resources) and implements changes to data standards or norms . |
| Example Alternative PEP Backbone Prescription |
This is an example of an alternative PEP backbone prescription resource based on the AltPepBackbonePrescription profile. |
| Example Alternative Third PEP Prescription |
This is an example of an alternative Third PEP prescription resource based on the AltThirdPepPrescription profile. |
| Example Current PrEP Regimen Prescription |
This is an example of a current PrEP regimen prescription resource based on the CurrentPrepRegimen profile. |
| Example Elevated HIV Risk Condition |
This is an example of an Elevated HIV Risk Condition resource based on the HivElevatedRiskForAcquisition profile. |
| Example HIV Key Population Observation |
This is an example of an HIV Key Population Observation resource based on the HivKeyPopulation profile. |
| Example HIV On ART Medication Statement |
This is an example of an On ART Medication Statement resource based on the HivOnArtMedicationStatement profile. |
| Example HIV Positive Status Condition |
This is an example of an HIV Positive Status Condition resource based on the HivStatusCondition profile. |
| Example HIV Positive Status Observation |
This is an example of an HIV Positive Status Observation resource based on the HivStatusObservation profile. |
| Example HIV Test Observation for Positive Result |
This is an example of an HIV Test Observation resource based on the HivTest profile for a positive test result. |
| Example PrEP Product Prescription |
This is an example of a PREP Product Prescription resource based on the PrepProductPrescription profile. |
| Example Preferred PEP Backbone Prescription |
This is an example of a preferred PEP backbone prescription resource based on the PreferredPepBackbonePrescription profile. |
| Example Preferred Third PEP Prescription |
This is an example of a preferred third PEP prescription resource based on the PreferredThirdPepPrescription profile. |
| ExampleHivPatient | |
| Following up and contacting clients |
Functional Requirements For Following up and contacting clients |
| HIV non Functional Requirements |
Non Functional Requirements For HIV |
| HIV testing services |
Functional Requirements For HIV testing services |
| HIV.IND.11 OAMT coverage |
% of opioid dependent people receiving opioid agonist maintenance treatment (OAMT) at a specified date |
| HIV.IND.12 Total person-years on OAMT |
% of person-years of follow-up (PYFU) on OAMT among opioid dependent people |
| HIV.IND.13 OAMT minimum duration |
% of OAMT recipients who received treatment for at least six months |
| HIV.IND.14 OAMT minimum dose |
% of OAMT recipients receiving a maintenance dose greater than or equal to the recommended minimum dose |
| HIV.IND.15 VMMC scale-up |
Total number of voluntary medical male circumcisions (VMMCs) performed according to national standard during the reporting period |
| HIV.IND.16 VMMC adverse events |
a) Number or (b) % of adverse events during the reporting period |
| HIV.IND.18 People living with HIV who know their HIV status (first 95) |
Number and % of people living with HIV who know their HIV status |
| HIV.IND.19 HTS test volume and positivity |
Number of HIV tests performed (volume) and the % of HIV-positive results returned to people (positivity) |
| HIV.IND.2 Total PrEP recipients |
Number of people who received PrEP at least once during the reporting period |
| HIV.IND.20 Individuals testing positive for HIV |
% testing positive among people who received an HIV test in the reporting period |
| HIV.IND.21 Linkage to ART |
% of people newly diagnosed with HIV initiated on ART |
| HIV.IND.22 HTS partner services |
Number of people who were identified and tested using partner testing services and who received their results |
| HIV.IND.24 HTS linkage to prevention |
Among those testing HIV-negative and identified as being at elevated risk for HIV acquisition, % of people who receive an HIV prevention intervention within defined period |
| HIV.IND.25 HIV retesting coverage |
% of people testing HIV-negative who tested again within a defined period of time after their previous test |
| HIV.IND.27 People living with HIV on ART |
Number and % of people on ART among all people living with HIV at the end of the reporting period |
| HIV.IND.28 Total attrition from ART |
Number and % of people living with HIV on ART at the end of the last reporting period and those newly initiating ART during the current reporting period who were not on ART at the end of the current reporting period |
| HIV.IND.29 People living with HIV on ART who have suppressed viral load |
% of people living with HIV on ART (for at least six months) who have virological suppression |
| HIV.IND.3 PrEP coverage |
% of people prescribed PrEP among those identified as being at elevated risk for HIV acquisition |
| HIV.IND.30 New ART patients |
Number of people living with HIV who initiated ART |
| HIV.IND.31 Late ART initiation |
% of people living with HIV who initiate ART with a CD4 count of <200 cells/mm3 |
| HIV.IND.32 Viral load testing coverage |
% of people living with HIV on ART (for at least six months) with viral load test results |
| HIV.IND.33 Early viral load testing (at six months) |
Number and % of people living with HIV on ART who had a viral load result reviewed by six months after initiation of ART |
| HIV.IND.34 Appropriate second viral load test after adherence counselling |
% of people living with HIV receiving ART with VL ≥1000 copies/mL who received a follow-up viral load test within three months |
| HIV.IND.35 ARV toxicity prevalence |
% of ART patients with treatment-limiting ARV toxicity |
| HIV.IND.37 Viral suppression at labour and delivery |
% of HIV-positive pregnant women who are virally suppressed at labour and delivery |
| HIV.IND.38 Early infant diagnosis (EID) coverage |
% of HIV-exposed infants who receive a virological test for HIV within two months (and 12 months) of birth |
| HIV.IND.39 Infant ARV prophylaxis coverage |
% of HIV-exposed infants who initiated ARV prophylaxis |
| HIV.IND.4 Volume of PrEP prescribed |
Total volume of PrEP product prescribed |
| HIV.IND.40 ART coverage in pregnant women |
% of HIV-positive pregnant women who received ART during pregnancy and/or at labour and delivery |
| HIV.IND.41 ART coverage in breastfeeding mothers |
% of HIV-exposed breastfeeding infants whose mothers are receiving ART at 12 (and 24 months) postpartum |
| HIV.IND.42 Final outcome of PMTCT |
% of HIV-exposed infants whose final HIV outcome status is known |
| HIV.IND.43 HIV prevalence among women attending ANC |
% of pregnant women who are HIV-positive at the time of their first test during the current pregnancy |
| HIV.IND.44 TPT initiation |
Number and % of eligible people living with HIV on ART who initiated TB preventive treatment |
| HIV.IND.45 TPT completion |
Number and % of people living with HIV on ART who completed a course of TB preventive treatment among those who initiated TPT |
| HIV.IND.46 TB diagnostic testing type |
% of people living with HIV with TB symptoms who receive a rapid molecular test, for example, Xpert MTB/RIF, as a first test for diagnosis of TB |
| HIV.IND.47 People living with HIV with active TB disease |
% of people living with HIV newly initiated on ART who have active TB disease |
| HIV.IND.48 TB screening coverage among new ART patients |
% of people living with HIV newly initiated on ART who were screened for TB |
| HIV.IND.49 TB symptom-screened positive among new ART patients |
% of people living with HIV newly initiated on ART who were screened for TB symptoms and who screened positive |
| HIV.IND.5 Number of PEP recipients |
Number of people prescribed PEP during the reporting period |
| HIV.IND.50 TB testing among those symptom-screened positive |
% of people living with HIV newly initiated on ART and screened positive for TB symptoms who then are tested for TB |
| HIV.IND.51 TB diagnosis among those tested for TB |
% of people living with HIV newly initiated on ART and tested for TB who are diagnosed with active TB disease |
| HIV.IND.52 TB treatment initiation among diagnosed |
% of people living with HIV newly initiated on ART and diagnosed with active TB who initiated TB treatment |
| HIV.IND.53 Multi-month ARV dispensing |
% of people living with HIV and On ART who are receiving multi-month dispensing of ARV medicine during the reporting period |
| HIV.IND.54 Uptake of DSD ART models among people living with HIV |
% of people newly enrolled in DSD ART models among those eligible |
| HIV.IND.55 Coverage of DSD ART models among people living with HIV on ART |
% of people living with HIV enrolled in DSD ART models among those eligible for DSD ART (for facilities with electronic HIS) or among people living with HIV On ART (facilities with paper-based systems) during the reporting period |
| HIV.IND.56 Retention in DSD ART models |
% of people retained in DSD ART models during the reporting period |
| HIV.IND.57 Viral suppression among people living with HIV engaged in DSD ART models |
% of people living with HIV engaged in DSD ART models who have virological suppression |
| HIV.IND.58 Syphilis testing coverage, HIV prevention services |
% of people attending HIV prevention services who were tested for syphilis during the reporting period |
| HIV.IND.59 Syphilis testing coverage, HIV-positive clients |
% of people living with HIV who were tested for syphilis during the reporting period |
| HIV.IND.6 PEP completion |
% of PEP recipients completing PEP course |
| HIV.IND.60 Syphilis testing coverage, pregnant women, first ANC visit |
% of pregnant women who were tested for syphilis on first ANC services visit during the reporting period |
| HIV.IND.61 Syphilis testing coverage, pregnant women, any ANC visit |
% of pregnant women who were tested for syphilis on any ANC visit during the reporting period |
| HIV.IND.62 Syphilis test positivity, HIV prevention services |
% of people attending HIV prevention services who were tested for syphilis and had a positive syphilis test result during the reporting period |
| HIV.IND.63 Syphilis test positivity, HIV-positive clients |
% of people living with HIV who were tested for syphilis and had a positive syphilis test result during the reporting period |
| HIV.IND.64 Syphilis test positivity, pregnant women, first visit |
% of pregnant women who tested positive for syphilis during first ANC services visit in the reporting period |
| HIV.IND.65 Syphilis test positivity, pregnant women, any visit |
% of pregnant women who tested positive for syphilis during the reporting period |
| HIV.IND.66 Syphilis treatment coverage, HIV prevention services |
% of people attending HIV prevention services tested positive for syphilis who were treated based on national guidelines during the reporting period |
| HIV.IND.67 Syphilis treatment coverage, HIV-positive clients |
% of people living with HIV tested positive for syphilis who were treated based on national guidelines during the reporting period |
| HIV.IND.68 Syphilis treatment coverage, pregnant women, first ANC visit |
% of pregnant women tested positive for syphilis on first ANC services visit who were treated based on national guidelines during the reporting period |
| HIV.IND.69 Syphilis treatment coverage, pregnant women, any ANC visit |
% of pregnant women who tested positive for syphilis who were treated based on national guidelines during the reporting period |
| HIV.IND.7 HIV in PEP recipients |
% of PEP recipients testing HIV-positive three months after PEP was prescribed |
| HIV.IND.70 Gonorrhoea testing coverage, HIV prevention services |
% of people attending HIV prevention services tested for gonorrhoea during the reporting period |
| HIV.IND.71 Gonorrhoea testing coverage, HIV-positive clients |
% of people living with HIV tested for gonorrhoea during the reporting period |
| HIV.IND.72 Gonorrhoea test positivity, HIV prevention services |
% of people who tested positive for gonorrhoea during the reporting period |
| HIV.IND.73 Gonorrhoea test positivity, HIV-positive clients |
% of people living with HIV who tested positive for gonorrhoea during the reporting period |
| HIV.IND.74 Gonorrhoea treatment coverage, HIV prevention services |
% of people attending HIV prevention services tested positive for gonorrhoea who were treated based on national guidelines during the reporting period |
| HIV.IND.75 Gonorrhoea treatment coverage, HIV-positive clients |
% of people living with HIV tested positive for gonorrhoea who were treated based on national guidelines during the reporting period |
| HIV.IND.76 Presence of STI syndrome, HIV prevention services |
% of people attending HIV prevention services diagnosed with a particular STI syndrome during the reporting period |
| HIV.IND.77 Presence of STI syndrome, HIV-positive clients |
% of people living with HIV diagnosed with a particular STI syndrome during the reporting period |
| HIV.IND.78 Repeat diagnosis of STI syndrome, HIV prevention services |
% of people attending HIV prevention services diagnosed with a particular STI syndrome who were diagnosed with the same STI syndrome two or more times during the reporting period |
| HIV.IND.79 Repeat diagnosis of STI syndrome, HIV-positive clients |
% of people living with HIV diagnosed with a particular STI syndrome who were diagnosed with the same STI syndrome two or more times during the reporting period |
| HIV.IND.8 NSP coverage |
% of people who inject drugs provided with needles-syringes during the reporting period |
| HIV.IND.80 HBV test coverage, HIV prevention services |
% of people attending HIV prevention services who were tested for hepatitis B surface antigen (HBsAg) during the reporting period (laboratory-based test or rapid test) |
| HIV.IND.81 HBV test coverage, HIV-positive clients |
% of people living with HIV who were tested for hepatitis B surface antigen (HBsAg) during the reporting period (laboratory-based test or rapid test) |
| HIV.IND.82 HBV test coverage, pregnant women |
% of pregnant women who were tested for hepatitis B surface antigen (HBsAg) during the reporting period (laboratory-based test or rapid test) |
| HIV.IND.83 HCV test coverage, HIV prevention services |
% of people attending HIV prevention services who were tested for HCV (HCV antibody, HCV RNA or HCV core antigen) during the reporting period (laboratory-based test or rapid test) |
| HIV.IND.84 HCV test coverage, HIV-positive clients |
% of people living with HIV who were tested for HCV (HCV antibody, HCV RNA or HCV core antigen) during the reporting period (laboratory-based test or rapid test) |
| HIV.IND.85 HBsAg positivity, HIV prevention services |
Percentage of people attending HIV prevention services who were tested for HBsAg and had a positive HBsAg test during the reporting period |
| HIV.IND.86 HBsAg positivity, HIV-positive clients |
Percentage of people living with HIV who were tested for HBsAg and had a positive HBsAg test during the reporting period |
| HIV.IND.87 HBsAg positivity, pregnant women |
Percentage of pregnant women who were tested for HBsAg and had a positive HBsAg test during the reporting period |
| HIV.IND.88 HCV positivity, HIV prevention services |
% of people attending HIV prevention services with a positive HCV test result (HCV antibody, HCV RNA (PCR) or HCV core antigen) during the reporting period |
| HIV.IND.89 HCV positivity, HIV-positive clients |
% of people living with HIV with a positive HCV test result (HCV antibody, HCV RNA (PCR) or HCV core antigen) during the reporting period |
| HIV.IND.9 Regular NSP access |
% of people who inject drugs accessing a needle-syringe programme (NSP) at least once per month during the reporting period |
| HIV.IND.90 HBV treatment among people living with HIV |
% of people living with HIV and diagnosed with HBV infection who are on TDF-based ART |
| HIV.IND.91 HCV treatment among people living with HIV |
% of people living with HIV and diagnosed with HCV infection who initiated HCV treatment (direct acting antivirals) during the reporting period |
| HIV.IND.92 HCV cured among people living with HIV |
% of people living with HIV and co-infected with HCV who were confirmed to be cured of HCV during the reporting period |
| HIV.IND.93 Cervical cancer screening |
Number of women living with HIV who were screened for cervical cancer using any screening test |
| HIV.IND.94 Pre-invasive cervical disease treatment |
% of women living with HIV who screened positive for pre-invasive cervical disease and received treatment for it |
| HIV.IND.95 Invasive cervical cancer treatment |
% of women living with HIV diagnosed with invasive cancer who were treated |
| HIV.IND.96 Cervical cancer survival |
Crude probability of surviving 1 year after a diagnosis of cervical cancer |
| Key populations |
A member of a key population is someone who, due to specific higher-risk behaviours, is at an increased risk of HIV irrespective of the epidemic type or local context. Key population groups also often have legal and social issues related to their behaviours that increase their vulnerability to HIV. Five key populations are included in this kit: (1) men who have sex with men, (2) people who inject drugs, (3) people in prisons and other closed settings, (4) sex workers and (5) transgender people. Key populations are important to the dynamics of HIV transmission and are essential partners in an effective response to the epidemic. |
| Lab technician |
A person who performs clinical tests on specimens of bodily fluids and tissues in order to get information about the health of a patient, as well as conducts tests and operates equipment for analysis of biological material, including blood and urine. This person normally has completed formal training in biomedical science, medical technology or a related field. |
| Nurse |
A graduate who has been legally authorized (registered) to practice after examination by a state board of nurse examiners or similar regulatory authority. Education includes three, four or more years in nursing school, and it leads to a university or postgraduate university degree or the equivalent. A registered nurse has the full range of nursing skills. |
| Pharmacist |
The pharmacist stores, preserves, compounds and dispenses medicinal products, as well as counsels on the proper use and adverse effects of drugs and medicines following prescriptions issued by other health professionals. This individual has completed university-level training in pharmacy or pharmaceutical chemistry. |
| Physician |
A legally qualified and licensed practitioner of medicine, concerned with maintaining or restoring human health through the study, diagnosis and treatment of disease and injury, through the science of medicine and the applied practice of that science. A medical doctor requires training in a medical school. Gaining a basic medical degree may take from five to nine years, depending on the jurisdiction and the university providing the training. |
| PrEP visit |
Functional Requirements For PrEP visit |
| Referral |
Functional Requirements For Referral |
| Registration |
Functional Requirements For Registration |
| Special population client |
A person from a specific group that requires or would benefit from differentiated client management or services. The groups may include key populations, paediatric or adolescent clients, adolescent girls and young women, pregnant or breastfeeding women, tuberculosis (TB) patients, serodiscordant partners and other specific priority populations. |
| Specialist medical doctor |
A doctor who diagnoses, treats and prevents illness, disease, injury and other impairments using specialized testing and diagnostic, medical, surgical, physical and psychiatric techniques. These providers may also plan, supervise and evaluate the implementation of care and treatment plans by other health care providers. They specialize in certain disease categories, types of clients or methods of treatment and may conduct medical education and research activities in their chosen areas of specialization. |
| Trained lay provider |
A person who has been trained and supervised to independently perform functions related to health care delivery and to deliver specific services but who has received no formal professional or paraprofessional certificate or tertiary educational degree. Peers can be trained to function as lay providers. |
| Trained non-physician clinician |
A professional health worker who is capable of many of the diagnostic and clinical functions of a physician but who is not trained as a physician. These types of health workers are an important cadre for HIV care and treatment in some countries. Normally, completion of tertiary-level training in theoretical and practical medical services. They work autonomously or with limited supervision of medical doctors and provide advisory, diagnostic, curative and preventive medical services more limited in scope and complexity than those carried out by medical doctors. |